Nexstim
Nexstim is a medical device company developing “NBS”–a noninvasive, image-guided TMS for brain diagnostics and therapy..
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | €750k | Post IPO Convertible |
| Total Funding | 000k | ||
| EUR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 56 % | 49 % | (24 %) | 21 % | 71 % | 24 % | 12 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 16 % | 20 % | (7 %) | 5 % | 25 % | 30 % | 31 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (13 %) | 14 % | (18 %) | (10 %) | 17 % | 22 % | 26 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 14 % | 8 % | 8 % | 6 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Nexstim Plc is a medical technology company specializing in non-invasive brain stimulation (TMS) technology. The company operates primarily in the healthcare sector, serving neurosurgeons and medical professionals who require precise and reliable brain imaging and stimulation solutions. Nexstim's core product is its FDA-cleared TMS technology, which uses advanced 3D imaging to accurately target the electric field (E field) in the brain, providing drug-free therapy for various neurological conditions. The technology is based on decades of scientific research and is designed to offer unmatched accuracy and precision, making it a valuable tool for neurosurgeons and clinicians.
Nexstim generates revenue through the sale of its TMS systems, as well as through service contracts and system upgrades. The company has a strong presence in Europe, with recent orders from Germany and Sweden, and is expanding its market reach globally. Nexstim's business model focuses on continuous innovation and improvement of its technology to meet the evolving needs of the medical community.
The company also engages in research and development to explore new applications for its TMS technology, including risk stratification for patients with functionally eloquent tumors. Nexstim's management team, led by CEO Mikko Karvinen and CFO Joonas Juokslahti, is committed to driving growth and enhancing shareholder value through strategic initiatives and operational excellence.
Keywords: TMS technology, 3D imaging, brain therapy, neurosurgeons, FDA-cleared, non-invasive, drug-free, medical technology, risk stratification, healthcare.